Events
FDLI Virtual Program: What Patient Organizations Should Know to Interact with FDA During COVID-19
September 2, 2020

On September 2, Axinn partner Chad Landmon participated in an FDLI virtual program entitled, "What Patient Organizations Should Know to Interact with FDA During COVID-19."

Panelists provided an overview of FDA’s COVID-19 medical product response and addressed the impact of the pandemic on medical product development and FDA priorities and personnel. 

By using the Axinn, Veltrop & Harkrider LLP website with cookies enabled on your browser, you agree to our use of cookies during your browsing experience. Learn more about our privacy policy.